BOTHELL, Wash.--(BUSINESS WIRE)--Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced today that it has extended its collaboration agreement with the Institute for Systems Biology (ISB). The goal of the collaboration is to use Lumera’s ProteomicProcessor™ to identify biomarkers associated with drug toxicity and cancer.
